PR

Press Release

scroll

International PR

press release

Title ExoCoBio Named One of Top 4 Most Richly Funded Exosome Startups by Bioinformant
writer exocobio
date 2020-07-30

   A global biotech startup in Exosome field is getting worldwide


attention with its excellent technology and feasibility.




ExoCoBio Inc. has been named one of 'Top 4 Most Richly


Funded Exosome Startups' uncased by 'Bioinformant' which


is a global market research company specialized in stem cell.





  ExoCoBio Inc. succeeded in series A investment totaling KRW


12.5 billion only in about 100 days from its foundation in last


April. Following this, they presented a thesis to confirm the stem


cell exosome's feasibility in atopic dermatitis improvement and


successfully completed Series B investment of KRW 30 billion


in September. It ranks 1st track record in Korea and 3rd in


World investment performance.




  Moreover, August 2018, ExoCoBio Inc. launched derma-


cosmetic brand 'Celltweet' which contains ASC-EXOSOME™,


an ingredient applied for a patent. 'Celltweet' is a compound


word of 'cell' and 'tweet' meaning exosome, neurotransmitter


between cells, resolves various skin stresses quickly.




                                                                                                                   <BusinessNewsWire> 2018. 10.31
다운로드수 0